A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
DRUG

Delafloxacin

300mg IV every 12 hours for 5-14 days

DRUG

Linezolid

600mg IV every 12 hours for 5-14 days

DRUG

Vancomycin

15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days

Trial Locations (31)

10467

Montefiore Medical Center, The Bronx

19713

Christiana Care Health Services, Newark

30030

Atlanta Institute for Medical Research, Inc, Decatur

31406

Southeast Regional Research Group, Savannah

31904

Southeast Regional Research Group, Columbus

32132

Riverside Clinical Research, Edgewater

32207

River City Clinical Research, Jacksonville

32811

Central Florida Internists Medical, Orlando

33617

Ronald Barbour, MD, Temple Terrace

34741

Central Florida Internists, Kissimmee

34769

Central Florida Internists, Saint Cloud

36106

Drug Research and Analysis Corp, Montgomery

36617

University of South Alabama Medical Center, Mobile

42003

Four Rivers Clinical Research, Inc, Paducah

43215

Remington-Davis, Inc., Columbus

45801

Ravi Kamepalli, MD, Lima

57702

Health Concepts, Rapid City

59701

Mercury Street Medical Group, PLLC, Butte

65212

University of Missouri Health Care, Columbia

66160

University of Kansas Medical Center, Kansas City

70810

Medical Development Centers, LLC, Baton Rouge

77002

Jennifer Johnson-Caldwell, MD, Houston

77005

Alan Nolasco, MD, Houston

89109

eStudySite, Las Vegas

90015

HealthCare Partners Medical Group, Los Angeles

90620

Southbay Pharma Research, Buena Park

91105

HealthCare Partners Medical Group, Pasadena

91911

eStudySite, Chula Vista

91942

eStudySite, La Mesa

92056

eStudySite, Oceanside

08244

South Jersey Infectious Disease, Somers Point

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY